Global Opioid Use Disorder (OUD) Market Size To Grow USD 7.8 Billion by 2032 | CAGR of 10.7%
Category: HealthcareGlobal Opioid Use Disorder (OUD) Market Size To Grow USD 7.8 Billion by 2032
According to a research report published by Spherical Insights & Consulting the Global Opioid Use Disorder (OUD) Market Size is To Grow from USD 2.8 Billion in 2022 to USD 7.8 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 10.7% during the forecast period.
Get more details on this report -
Browse key industry insights spread across 200 pages with 110 Market data tables and figures & charts from the report on the "Global Opioid Use Disorder (OUD) Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022– 2032." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/opioid-use-disorder-oud-market
Opioids are synthesized in laboratories to mimic the chemical properties of opioids, which interact with opioid receptors on nerve cells in the body and brain to reduce pain. They are a class of drugs that includes prescription pain treatments, synthetic opioids, and heroin. Prescription opioids are intended for the treatment of acute pain caused by an accident or surgery, chronic pain, active-phase cancer therapy, palliative care, and end-of-life care. Many patients rely on prescription opioids to help them manage their symptoms while under the care of a doctor. Opioid use disorder is a chronic lifelong illness with serious consequences such as disability, relapses, and death.
An increasing number of people are suffering from severe and chronic ailments such as cancer, cardiovascular disease, accident pain, and other problems. These illnesses typically cause chronic pain, which is managed with the use of medications, primarily opioids. While the pain subsides, the patient is more prone to get addicted to these medications. These medications develop a dependency, and abrupt discontinuation may produce withdrawal symptoms in the patient. Furthermore, the adverse effects of the pharmaceuticals used to treat opioid addiction are predicted to stymie the market over the forecast period. Muscle soreness, vomiting, diarrhea, constipation, breathing problems, bone/joint pain, bladder discomfort, and stomach cramps are all frequent side effects of these drugs. In severe cases of a drug's poor reaction, the patient may experience depression and other psychological difficulties.
Covid 19 Impacts
The COVID-19 epidemic is expected to have a mixed influence on the growth of the OUD industry. The epidemic has put a strain on the world's healthcare system. All medical resources were dedicated to COVID-19 patients, therefore all elective procedures were postponed in 2020. The reduction in the number of scheduled operations is expected to reduce the need for opioids for pain treatment, resulting in a reduction in the prevalence of OUD. However, during the epidemic, the cancellation of doctor's appointments boosted long-term opioid use. This enhanced the prevalence of OUD illness. Opioid overdose is a prominent cause of death in the United States.
The buprenorphine segment is influencing the market with the largest market share over the forecast period.
The global opioid use disorder (OUD) market is divided into three segments based on pharmacological class such as buprenorphine, methadone, and naltrexone. The buprenorphine segment dominates the market with the largest revenue share during the forecast period, owing to increased usage of buprenorphine as an effective choice to treat opioid dependency, reduce cravings, and improve the quality of life for patients undergoing addiction treatment, accounting for the largest proportion of the market. Buprenorphine is now accessible in two forms: alone and in combination with the opioid receptor antagonist naloxone. Both buprenorphine formulations are effective in treating opioid use disorders.
The parenteral segment is dominating the largest market share during the forecast period.
The global opioid use disorder (OUD) market is segmented into two segments based on the route of administration such as oral and parenteral. The parenteral segment dominates the market due to the availability of several types of OUD drugs in various dosages in parenteral form. As a result, the parenteral form of medicine administration maintains its global market domination.
The hospitals segment is dominating the largest market share during the forecast period.
The worldwide opioid use disorder (OUD) market is segmented by distribution channel, which includes hospitals, private clinics, home care, and others. Hospitals dominate the market due to the patient population's reliance on this channel for the administration of parenteral OUD drugs such as buprenorphine.
North America led the market with the largest market revenue of over 49.3% during the forecast period
Get more details on this report -
North America is expected to lead substantial market expansion throughout the projection period owing to an increase in the number of products released for the treatment of opioid use disorder, an increase in opioid prescriptions, an increase in opioid users, an increase in opioid overdose fatalities, and a well-established opioid business in North America.
Asia Pacific is expected to grow fast throughout the forecast period owing to the figure of senior people, the rise in the awareness about accessibility of healthcare services, and the escalation in the number of chronic conditions.
Major vendors in Global Opioid Use Disorder (OUD) Market include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc. (Mylan N.V.), Hikma Pharmaceuticals PLC, Camurus, and Other key players.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In March 2023, Indivior PLC finalized the acquisition of Opiant Pharmaceuticals, Inc. Opiant has an experimental opioid overdose therapy candidate called OPNT003. Indivior's position in addiction treatment will be strengthened by the purchase.
- In February 2021, Orexo AB announced a collaboration with ApexB.io and Magellan Rx Management to do more research on the use of media, a digital treatment designed for people suffering from opioid use disorder (OUD), via the development of a unique, real-world evidence method. Media provides OUD patients with access to individualized, interactive psychotherapy sessions via their mobile device or PC.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Opioid Use Disorder (OUD) Market based on the below-mentioned segments:
Global Opioid Use Disorder (OUD) Market, By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
Global Opioid Use Disorder (OUD) Market, By Route of Administration
- Oral
- Parenteral
Global Opioid Use Disorder (OUD) Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
Opioid Use Disorder (OUD) Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Uk
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?